About Endogenous retrovirus group V member 2 Env polyprotein
Endogenous retrovirus group V member 2 Env polyprotein (ERVV-2) is a protein
from Homo sapiens identified by UniProt accession
B6SEH9, 535 residues long.
MolForge cross-references it against 0 known binders and
4 disease associations.
Target properties
| Protein name | Endogenous retrovirus group V member 2 Env polyprotein |
|---|
| UniProt accession | B6SEH9 |
|---|
| Gene | ERVV-2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 535 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (4)
Diseases linked to this target (Open Targets).
- nonpapillary renal cell carcinoma · score 0.01
- neoplasm · score 0.01
- infection · score 0.00
- infect · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-B6SEH9-F1 | alphafold | PREDICTED | 46.13 | — |
Amino-acid sequence (535 residues)
MTEKFLFLYL SLLPMPLLSQ AQWNENSLVS FSKIIASGNH LSNCWICHNF ITRSSSYQYI LVRNFSLNLT FGSGIPEGQH KSVPLQVSLA NSAHQVPCLD LTPPFNQSSK TSFYFYNCSS LNQTCCPCPE GHCDRKNTSE EGFPSPTIHP MSFSPAGCHP NLTHWCPAKQ MNDYRDKSPQ NRCAAWEGKE LITWRVLYSL PKAHTVPTWP KSTVPLGGPL SPACNQTIPA GWKSQLHKWF DSHIPRWACT PPGYVFLCGP QKNKLPFDGS PKITYSTPPV ANLYTCINNI QHTGECAVGL LGPRGIGVTI YNTTQPRQKR ALGLILAGMG AAIGMIAPWG GFTYHDVTLR NLSRQIDNIA KSTRDSISKL KASIDSLANV VMDNRLALDY LLAEQGGVCA VINKSCCVYV NNSGAIEEDI KKIYDEATWL HDFGKGGASA RAIWEAVKSA LPSLNWFVPL LGPATVILLL FLFGPCFFNL LIKCVSSRIK QFHMKSPQME RYQLSVIGGP STYKHISPLD ASGQRFRETM EEFSL
Explore Endogenous retrovirus group V member 2 Env polyprotein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets